Semaglutide in Diabetes Treatments

According to recent research, semaglutide, which is included in diabetic and weight-loss drugs like Ozempic and Wegovy, may reduce the incidence of Alzheimer's disease (AD) in those with type 2 diabetes. According to research published in the journal Alzheimer's & Dementia, compared to alternative diabetic therapies, there is a 40% to 70% lower chance of acquiring AD.

Summary of the Alzheimer's Disease Study

• As the most common cause of dementia, Alzheimer's affects millions worldwide.
• Research compared the impact of semaglutide with seven other diabetes medications, such as metformin and insulin.
• Reported a 70% lower risk of Alzheimer's in patients randomized to semaglutide (vs.
• Semaglutide, a GLP-1 receptor agonist, protects brain function by reducing the levels of toxic proteins in the area responsible for memory (hippocampus), increases brain cell uptake of glucose to inhibit neurodegeneration, reduces plaques and release of pro-inflammatory cytokines, and normalizes blood sugar control.
• GLP-1 drugs seem to serve a double duty—we suspect why—current Alzheimer's treatment targets amyloid plaques, and these are related to diabetes and preventing dementia.
• Its importance in India is probably even greater given the high prevalence of type 2 diabetes and that GLP-1 drug has the opportunity to mitigate dementia symptoms.
• Investigating the efficacy of increased dosages of GLP-1 RAs for use against Alzheimer's disease.